Cherry Pun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cherry Pun has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Amanpreet Brar
Division of General Surgery, Department of Surgery University of Toronto Toronto ON Canada
1 shared publication Anna Marie MBChB Mulligan
Department of Laboratory Medicine and Pathobiology, University of Toronto
1 shared publication- Aysegul Sari
Izmir Kâtip Celebi University, Türkiye
1 shared publication - Carol Jane Swallow
Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada
1 shared publication Carol Swallow
Department of Surgery, University of Toronto, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada
1 shared publication- David Patrick Cyr
Department of Surgical Oncology Princess Margaret Cancer Centre and Mount Sinai Hospital Toronto ON Canada
1 shared publication
Latest Publications
- Open Access
- 27 August 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 457-470
Multifocal extramural venous invasion is a powerful predictor of adverse oncological outcomes in stages I– III colorectal cancer
Aims: This study aimed to determine the impact of venous invasion (VI) characteristics on oncological outcomes in colorectal cancer (CRC). Methods and Results: Resection specimens from 368 patients with TNM stages I–III CRC were assessed for VI including its presence/absence, location [intramural (IMVI) or extramural (EMVI)], number and size of the largest VI focus. VI and EMVI were identified in 55% and 32% of cases, respectively. EMVI, but not IMVI, was significantly associated with decreased 5‐year recurrence‐free survival (RFS) and disease‐specific survival (DSS) (hazard ratio [HR] 4.2, 95% confidence interval CI [2.6–6.9] and 3.7 [95% CI 1.9–6.9], p < 0.0001, respectively). Multifocal EMVI (mEMVI), defined as 2 or more EMVI foci, was identified in 67% of EMVI‐positive cases. In multivariable analysis, EMVI (HR 2.4 [95% CI 1.3–4.3], P = 0.003) and mEMVI (HR 2.4 [95% CI: 1.3–4.4], P = 0.02) were independently associated with RFS and demonstrated stronger associations than all other examined features, including T and N stage. These associations were maintained when the cohort was expanded to include 113 patients who received neoadjuvant therapy in addition to the original 368 patients who had not (‘expanded cohort’, n = 481). An increasing number of EMVI foci was significantly associated with decreased RFS and DSS ( P < 0.0001). Patients with >5 EMVI foci ( n = 31) had a particularly poor prognosis with 5‐year RFS and DSS of 29% and 56%, respectively. EMVI dimensions were not associated with oncological outcomes. Conclusions: Extramural location and multifocality are features of VI strongly associated with adverse oncological outcomes. If externally validated, incorporation of EMVI multifocality into future reporting protocols merits consideration.
- 27 August 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 457-470
Open AccessMultifocal extramural venous invasion is a powerful predictor of adverse oncological outcomes in stages I– III colorectal cancer
Aims: This study aimed to determine the impact of venous invasion (VI) characteristics on oncological outcomes in colorectal cancer (CRC). Methods and Results: Resection specimens from 368 patients with TNM stages I–III CRC were assessed for VI including its presence/absence, location [intramural (IMVI) or extramural (EMVI)], number and size of the largest VI focus. VI and EMVI were identified in 55% and 32% of cases, respectively. EMVI, but not IMVI, was significantly associated with decreased 5‐year recurrence‐free survival (RFS) and disease‐specific survival (DSS) (hazard ratio [HR] 4.2, 95% confidence interval CI [2.6–6.9] and 3.7 [95% CI 1.9–6.9], p < 0.0001, respectively). Multifocal EMVI (mEMVI), defined as 2 or more EMVI foci, was identified in 67% of EMVI‐positive cases. In multivariable analysis, EMVI (HR 2.4 [95% CI 1.3–4.3], P = 0.003) and mEMVI (HR 2.4 [95% CI: 1.3–4.4], P = 0.02) were independently associated with RFS and demonstrated stronger associations than all other examined features, including T and N stage. These associations were maintained when the cohort was expanded to include 113 patients who received neoadjuvant therapy in addition to the original 368 patients who had not (‘expanded cohort’, n = 481). An increasing number of EMVI foci was significantly associated with decreased RFS and DSS ( P < 0.0001). Patients with >5 EMVI foci ( n = 31) had a particularly poor prognosis with 5‐year RFS and DSS of 29% and 56%, respectively. EMVI dimensions were not associated with oncological outcomes. Conclusions: Extramural location and multifocality are features of VI strongly associated with adverse oncological outcomes. If externally validated, incorporation of EMVI multifocality into future reporting protocols merits consideration.
- Open Access
- 8 April 2025
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 6, 1001302
Vanishing bile duct syndrome in drug-induced liver injury: clinical and pathologic perspectives
Vanishing bile duct syndrome (VBDS) is a rare condition, representing approximately 0.5% of small bile duct diseases, characterized by progressive destruction of intrahepatic bile ducts, leading to ductopenia. This condition encompasses various etiologies, with drug-induced VBDS (D-VBDS) accounting for 7% of VBDS cases. D-VBDS arises from liver injury due to chemical drugs, traditional medicines, and dietary supplements, often resulting in inflammatory responses and necrosis of bile duct epithelium. Recent years have seen a rise in reported cases, making drug-related injuries a leading cause of acute liver failure in Western countries. This review provides a comprehensive analysis of VBDS, focusing on the histopathological features of acute and chronic D-VBDS, alongside exploring its clinical presentation, prognostic implications, and future research directions. Understanding the diverse etiologies, clinical manifestations, and biochemical parameters associated with D-VBDS is essential for improving diagnosis, treatment strategies, and patient outcomes.
- 8 April 2025
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 6, 1001302
Open AccessVanishing bile duct syndrome in drug-induced liver injury: clinical and pathologic perspectives
Vanishing bile duct syndrome (VBDS) is a rare condition, representing approximately 0.5% of small bile duct diseases, characterized by progressive destruction of intrahepatic bile ducts, leading to ductopenia. This condition encompasses various etiologies, with drug-induced VBDS (D-VBDS) accounting for 7% of VBDS cases. D-VBDS arises from liver injury due to chemical drugs, traditional medicines, and dietary supplements, often resulting in inflammatory responses and necrosis of bile duct epithelium. Recent years have seen a rise in reported cases, making drug-related injuries a leading cause of acute liver failure in Western countries. This review provides a comprehensive analysis of VBDS, focusing on the histopathological features of acute and chronic D-VBDS, alongside exploring its clinical presentation, prognostic implications, and future research directions. Understanding the diverse etiologies, clinical manifestations, and biochemical parameters associated with D-VBDS is essential for improving diagnosis, treatment strategies, and patient outcomes.
- 30 May 2023
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 47 (7) , 826-834
Mammary Spindle Cell Proliferations on Core Needle Biopsy
Mammary spindle cell proliferations (SCPs) encompass a wide range of lesions and can be challenging to accurately diagnose on core needle biopsies (CNBs). Most SCPs are excised for definitive diagnosis. In the era of minimally invasive therapy, some SCP may be followed conservatively. We aim to examine the spectrum of SCP diagnosed on CNB and evaluate if excision of benign/indeterminate SCP is always required. We identified patients with SCP across 3 institutions. The CNB were classified into benign, indeterminate, or malignant. Available excisional specimens were used to classify the lesion as benign or malignant. Clinical variables were reviewed. A total of 197 SCP met the inclusion criteria, including 100 (53%) CNB classified as benign, 52 (26%) indeterminate, and 36 (19%) malignant. Nine patients had excisions without a preceding CNB. Excision was performed in 47% of benign, 87% of indeterminate, and 86% malignant CNB. Of 123 excised SCP, 77 (63%) were benign, while 44 (36%) were malignant. Most benign lesions were not suspicious radiologically (67%), while indeterminate and malignant lesions were more likely to be suspicious (44% and 75%, respectively; P<0.001). Malignant lesions tended to present as larger, rapidly growing, masses. Most mammary SCP are benign (63% of excisions). Appropriate ancillary tests can safely exclude some malignant entities. We encourage narrowing down the differential diagnosis to pertinent entities based on clinical presentation, imaging, histology, immunohistochemistry, and molecular studies, if applicable. Patients with mammary SCP may be spared surgery provided accurate pathologic diagnosis and appropriate correlation with imaging and clinical data.
- 30 May 2023
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 47 (7) , 826-834
Mammary Spindle Cell Proliferations on Core Needle Biopsy
Mammary spindle cell proliferations (SCPs) encompass a wide range of lesions and can be challenging to accurately diagnose on core needle biopsies (CNBs). Most SCPs are excised for definitive diagnosis. In the era of minimally invasive therapy, some SCP may be followed conservatively. We aim to examine the spectrum of SCP diagnosed on CNB and evaluate if excision of benign/indeterminate SCP is always required. We identified patients with SCP across 3 institutions. The CNB were classified into benign, indeterminate, or malignant. Available excisional specimens were used to classify the lesion as benign or malignant. Clinical variables were reviewed. A total of 197 SCP met the inclusion criteria, including 100 (53%) CNB classified as benign, 52 (26%) indeterminate, and 36 (19%) malignant. Nine patients had excisions without a preceding CNB. Excision was performed in 47% of benign, 87% of indeterminate, and 86% malignant CNB. Of 123 excised SCP, 77 (63%) were benign, while 44 (36%) were malignant. Most benign lesions were not suspicious radiologically (67%), while indeterminate and malignant lesions were more likely to be suspicious (44% and 75%, respectively; P<0.001). Malignant lesions tended to present as larger, rapidly growing, masses. Most mammary SCP are benign (63% of excisions). Appropriate ancillary tests can safely exclude some malignant entities. We encourage narrowing down the differential diagnosis to pertinent entities based on clinical presentation, imaging, histology, immunohistochemistry, and molecular studies, if applicable. Patients with mammary SCP may be spared surgery provided accurate pathologic diagnosis and appropriate correlation with imaging and clinical data.
- Open Access
- 20 June 2022
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 31 (6) , 957-966
Prognostic Significance of Tumour Budding and Desmoplastic Reaction in Intestinal-Type Gastric Adenocarcinoma
Objective. Tumour budding and desmoplastic reactions in peritumoural stroma are features of the tumour microenvironment that are associated with colorectal cancer prognosis but have not been as thoroughly examined in gastric cancer. We aimed to further characterize the prognostic role of tumour budding and desmoplastic reaction in gastric adenocarcinoma with intestinal differentiation. Methods. 76 curative gastrectomy specimens were identified, excluding post-neoadjuvant cases or cases with >50% diffuse-type histology. Tumour budding was defined and graded according to the International Tumor Budding Consensus Conference recommendations and desmoplastic reaction was classified as described by Ueno et al 2017. Tumour budding and desmoplastic reaction were analyzed for associations with pathologic features and clinical outcomes. Results. Tumour budding was associated with pT ( P < .001), pN ( P < .004), overall stage ( P < .001), LVI ( P < .001) and PNI ( P = .002). Desmoplastic reaction was associated with pT ( P < .001), pN ( P = .005), overall stage ( P = .031) and PNI ( P < .001), but not LVI. Survival analysis showed decreased overall survival (OS) and recurrence-free survival (RFS) for intermediate and high grade tumour budding ( P = .031, .014 respectively). Immature stroma was significantly associated with RFS but not OS. Neither tumour budding nor desmoplastic reaction were independent predictors of OS or RFS on multivariate analysis in this cohort. Conclusion. Tumour budding and desmoplastic reaction were associated with known pathologic risk factors. Prognostically, tumour budding was associated with OS and RFS while desmoplastic reaction was associated with RFS only. Our data suggest that tumour budding and desmoplastic reaction have prognostic value in intestinal-type gastric adenocarcinoma.
- 20 June 2022
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 31 (6) , 957-966
Open AccessPrognostic Significance of Tumour Budding and Desmoplastic Reaction in Intestinal-Type Gastric Adenocarcinoma
Objective. Tumour budding and desmoplastic reactions in peritumoural stroma are features of the tumour microenvironment that are associated with colorectal cancer prognosis but have not been as thoroughly examined in gastric cancer. We aimed to further characterize the prognostic role of tumour budding and desmoplastic reaction in gastric adenocarcinoma with intestinal differentiation. Methods. 76 curative gastrectomy specimens were identified, excluding post-neoadjuvant cases or cases with >50% diffuse-type histology. Tumour budding was defined and graded according to the International Tumor Budding Consensus Conference recommendations and desmoplastic reaction was classified as described by Ueno et al 2017. Tumour budding and desmoplastic reaction were analyzed for associations with pathologic features and clinical outcomes. Results. Tumour budding was associated with pT ( P < .001), pN ( P < .004), overall stage ( P < .001), LVI ( P < .001) and PNI ( P = .002). Desmoplastic reaction was associated with pT ( P < .001), pN ( P = .005), overall stage ( P = .031) and PNI ( P < .001), but not LVI. Survival analysis showed decreased overall survival (OS) and recurrence-free survival (RFS) for intermediate and high grade tumour budding ( P = .031, .014 respectively). Immature stroma was significantly associated with RFS but not OS. Neither tumour budding nor desmoplastic reaction were independent predictors of OS or RFS on multivariate analysis in this cohort. Conclusion. Tumour budding and desmoplastic reaction were associated with known pathologic risk factors. Prognostically, tumour budding was associated with OS and RFS while desmoplastic reaction was associated with RFS only. Our data suggest that tumour budding and desmoplastic reaction have prognostic value in intestinal-type gastric adenocarcinoma.